Cartesian Therapeutics (RNAC) Income from Continuing Operations (2015 - 2026)
Cartesian Therapeutics (RNAC) reported Income from Continuing Operations of 25473000.0 for Q1 2026, down 28.17% year-over-year from 35464126.23 in Q1 2025, and up 67.08% quarter-over-quarter from 77371000.0 in Q4 2025.
Cartesian Therapeutics (RNAC) Income from Continuing Operations (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has 12 years of Income from Continuing Operations data on file, last reported at 25473000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 25473000.0, down 28.17% year-over-year; the trailing twelve-month figure through Mar 2026 was 142425000.0 (down 222.22% YoY), and the FY2025 annual result was 130302000.0, down 68.27% from the prior year.
- Income from Continuing Operations climbed to 25473000.0 in Q1 2026 per RNAC's latest filing, from 77371000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 14952000.0 in Q2 2024 and troughed at 196658000.0 in Q4 2023.
- A 5-year average of 24640647.06 and a median of 17858000.0 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations jumped 5505.67% in 2022, then tumbled 3437.15% in 2023.
- A 5-year view of Income from Continuing Operations shows it stood at 5893000.0 in 2022, then plunged by 3437.15% to 196658000.0 in 2023, then soared by 87.66% to 24277000.0 in 2024, then plunged by 218.7% to 77371000.0 in 2025, then surged by 67.08% to 25473000.0 in 2026.
- Business Quant data shows RNAC's Income from Continuing Operations at 25473000.0 in Q1 2026, 77371000.0 in Q4 2025, and 19518000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Cartesian Therapeutics | 261.84 Mn | 261.84 Mn | - | -25.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -25.47 Mn |
| Dec 31, 2025 | -77.37 Mn |
| Sep 30, 2025 | -19.52 Mn |
| Jun 30, 2025 | -20.06 Mn |
| Mar 31, 2025 | -19.87 Mn |
| Dec 31, 2024 | -24.28 Mn |
| Sep 30, 2024 | -15.00 Mn |
| Jun 30, 2024 | 14.95 Mn |
| Mar 31, 2024 | -12.18 Mn |
| Dec 31, 2023 | -196.66 Mn |
| Sep 30, 2023 | -9.00 Mn |
| Jun 30, 2023 | -18.00 Mn |
| Mar 31, 2023 | -17.86 Mn |
| Dec 31, 2022 | 5.89 Mn |
| Sep 30, 2022 | -7.89 Mn |
| Jun 30, 2022 | 13.35 Mn |
| Mar 31, 2022 | 10.08 Mn |
| Dec 31, 2021 | 12.24 Mn |
| Sep 30, 2021 | -17.89 Mn |
| Jun 30, 2021 | -247,000.00 |